152 related articles for article (PubMed ID: 12388670)
21. Substituted amphetamines that produce long-term serotonin depletion in rat brain ("neurotoxicity") do not decrease serotonin transporter protein expression.
Rothman RB; Jayanthi S; Cadet JL; Wang X; Dersch CM; Baumann MH
Ann N Y Acad Sci; 2004 Oct; 1025():151-61. PubMed ID: 15542713
[TBL] [Abstract][Full Text] [Related]
22. Repeated administration of the substituted amphetamine p-methoxyamphetamine produces reductions in cortical 5-HT transporter binding but not 5-HT content, unlike 3,4-methylenedioxyamethamphetamine.
Callaghan PD; Farrand K; Salem A; Hughes P; Daws LC; Irvine RJ
Eur J Pharmacol; 2006 Sep; 546(1-3):74-81. PubMed ID: 16925993
[TBL] [Abstract][Full Text] [Related]
23. Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine.
Shankaran M; Yamamoto BK; Gudelsky GA
Eur J Pharmacol; 1999 Dec; 385(2-3):103-10. PubMed ID: 10607865
[TBL] [Abstract][Full Text] [Related]
24. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons.
Battaglia G; Yeh SY; De Souza EB
Pharmacol Biochem Behav; 1988 Feb; 29(2):269-74. PubMed ID: 2452449
[TBL] [Abstract][Full Text] [Related]
25. The role of dopaminergic systems in the perinatal sensitivity to 3, 4-methylenedioxymethamphetamine-induced neurotoxicity in rats.
Aguirre N; Barrionuevo M; Lasheras B; Del Río J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1159-65. PubMed ID: 9732373
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the translocation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA/ecstasy) in synaptosomes: evidence for a presynaptic localization involving the serotonin transporter (SERT).
Kramer HK; Poblete JC; Azmitia EC
Neuropsychopharmacology; 1998 Oct; 19(4):265-77. PubMed ID: 9718590
[TBL] [Abstract][Full Text] [Related]
27. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines.
Xie T; Tong L; McLane MW; Hatzidimitriou G; Yuan J; McCann U; Ricaurte G
Neuropsychopharmacology; 2006 Dec; 31(12):2639-51. PubMed ID: 16452989
[TBL] [Abstract][Full Text] [Related]
28. Hyperthermia-enhanced serotonin (5-HT) depletion resulting from d-fenfluramine exposure is preventable.
Stewart CW; Slikker W
Life Sci; 1999; 65(15):1531-6. PubMed ID: 10574218
[TBL] [Abstract][Full Text] [Related]
29. Abnormal ACTH and prolactin responses to fenfluramine in rats exposed to single and multiple doses of MDMA.
Poland RE; Lutchmansingh P; McCracken JT; Zhao JP; Brammer GL; Grob CS; Boone KB; Pechnick RN
Psychopharmacology (Berl); 1997 Jun; 131(4):411-9. PubMed ID: 9226745
[TBL] [Abstract][Full Text] [Related]
30. Serotonin reuptake transporter deficiency modulates the acute thermoregulatory and locomotor activity response to 3,4-(±)-methylenedioxymethamphetamine, and attenuates depletions in serotonin levels in SERT-KO rats.
Lizarraga LE; Phan AV; Cholanians AB; Herndon JM; Lau SS; Monks TJ
Toxicol Sci; 2014 Jun; 139(2):421-31. PubMed ID: 24595820
[TBL] [Abstract][Full Text] [Related]
31. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response.
Broening HW; Bowyer JF; Slikker W
J Pharmacol Exp Ther; 1995 Oct; 275(1):325-33. PubMed ID: 7562567
[TBL] [Abstract][Full Text] [Related]
32. Role of brain nitric oxide in (+/-)3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats.
Zheng Y; Laverty R
Brain Res; 1998 Jun; 795(1-2):257-63. PubMed ID: 9622646
[TBL] [Abstract][Full Text] [Related]
33. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse.
O'Callaghan JP; Miller DB
J Pharmacol Exp Ther; 1994 Aug; 270(2):741-51. PubMed ID: 8071867
[TBL] [Abstract][Full Text] [Related]
34. Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor.
Hewton R; Salem A; Irvine RJ
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):1051-7. PubMed ID: 17714093
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice.
Achat-Mendes C; Ali SF; Itzhak Y
Neuropsychopharmacology; 2005 Jun; 30(6):1128-37. PubMed ID: 15688084
[TBL] [Abstract][Full Text] [Related]
36. An assessment of the acute effects of the serotonin releasers methylenedioxymethamphetamine, methylenedioxyamphetamine and fenfluramine on immunity in rats.
Connor TJ; Kelly JP; Leonard BE
Immunopharmacology; 2000 Mar; 46(3):223-35. PubMed ID: 10741902
[TBL] [Abstract][Full Text] [Related]
37. Tolerance to 3,4-methylenedioxymethamphetamine is associated with impaired serotonin release.
Jones K; Brennan KA; Colussi-Mas J; Schenk S
Addict Biol; 2010 Jul; 15(3):289-98. PubMed ID: 20477756
[TBL] [Abstract][Full Text] [Related]
38. Repeated intermittent methylenedioxymethamphetamine exposure protects against the behavioral and neurotoxic, but not hyperthermic, effects of an MDMA binge in adult rats.
Piper BJ; Ali SF; Daniels LG; Meyer JS
Synapse; 2010 Jun; 64(6):421-31. PubMed ID: 20169574
[TBL] [Abstract][Full Text] [Related]
39. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease.
Zolkowska D; Rothman RB; Baumann MH
J Pharmacol Exp Ther; 2006 Aug; 318(2):604-10. PubMed ID: 16644904
[TBL] [Abstract][Full Text] [Related]
40. Release of serotonin induced by 3,4-methylenedioxymethamphetamine (MDMA) and other substituted amphetamines in cultured fetal raphe neurons: further evidence for calcium-independent mechanisms of release.
Wichems CH; Hollingsworth CK; Bennett BA
Brain Res; 1995 Oct; 695(1):10-8. PubMed ID: 8574641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
